Vir Biotechnology’s SOLSTICE Data To Be Featured At The European Association For The Study Of The Liver Congress 2024
Vir Biotechnology, Inc. (NASDAQ:VIR) today announced the EASL Congress has changed the Company's Phase 2 SOLSTICE hepatitis delta presentation from a late-breaker poster to an oral presentation. The SOLSTICE data will be